

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>	ATTY DOCKET NO. 0040964-0002	SERIAL NO. 10/609,233 TBA
	FILING TBA	GROUP TBA 1616

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
M	5,376,666	12/27/1994	Duncia	514	303	11/30/1992
	6,559,313	05/06/2003	Myers, et al.	546	279.1	03/22/2002
	6,174,906	01/16/2001	Elliot, et al.	514	365	10/01/1999
	6,197,762	03/06/2001	Garvey, et al.	514	174	09/18/1998
	5,968,911	10/19/1999	Lawson, et al.	514	46	02/18/1997
	5,873,359	02/23/1999	Zapol, et al.	128	203.12	12/09/1994
	20020115655	08/22/2002	Mehanna, Ahmed S.	514	217.03	10/31/2001
	20010031738	10/18/2001	Schwarz, Margaret A.	514	44	12/15/2000
	20030078190	04/24/2003	Weinberg, Marc S.	514	1	05/24/2002
M	20020132787	09/19/2002	Eljamal, Mohammed, et al.	514	44	09/19/2002

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

M			Canadian Journal of Anesthesia, Volume 49, Number 9, November 2002, Excellence in clinically-related research and knowledge, Cardiothoracic Anesthesia, Respiration and Airway, Inhaled iloprost controls pulmonary hypertension after cardiopulmonary bypass, Kassiani Theodoraki MD DEAA, Panagiota Rellia MD, Apostolos Thanopoulos MD, Loukas Tsourelis MD, Dimitrios Zarkalis MD, Petros Sfyarakis MD, Theophani Antoniou MD
M			The England Journal of Medicine, Volume 327, July 9, 1992, Number 2, The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension, Stuart Rich, MD, Elizabeth Kaufman, RN, and Paul S. Levy, Sc.D

EXAMINER	DATE CONSIDERED 3/15/06
----------	--------------------------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY DOCKET NO. 0040964-0002	SERIAL NO. TBA
	FILING TBA	GROUP TBA

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

M		The Columbia Encyclopedia, Sixth Edition. 2001 beta-blocker www.bartleby.com/65/be/beta-b.html
M		Postgraduate Medicine, Beta blockers of CHF, Adrenergic blockade dramatically reduces morbidity and mortality, Ravi K. Garg, MD; Matthew J. Sorrentino, MD, Vol. 109/No. 3/ March 2001/ Postgraduate Medicine

EXAMINER	DATE CONSIDERED 3/15/06
----------	-------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

ATTY DOCKET NO.
0040964-0002

SERIAL NO.
TBA

FILING
TBA

GROUP
TBA

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

			What Atenolol is and What it Does, http://www.sunderland.ac.uk/~hs0dad/profile/atenolol/what.htm no date
			The Columbia Encyclopedia, Sixth Edition 2001, ACE inhibitor, http://www.bartleby.com/65/ac/ACE-i.html no date

EXAMINER

[Signature]

DATE CONSIDERED

3/15/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY DOCKET NO.
0040964-0002

SERIAL NO.

FILING

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

M		Eporprostenol (Prostacyclin) and Pulmonary Hypertension, 21 March 2000, Annals of Internal Medicine, Volume 132, Number 6
mi		Center Watch, Drugs Approved by the FDA, Drug Name: Remodulin (treprostinil) http://www.centerwatch.com/patient/drugs/dru785.html No date

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY DOCKET NO.
0040964-0002

SERIAL NO.

FILING

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Definition for: Eicosanoid, http://www.kumc.edu/instruction/medicine/pathology/ed/keywords/kw_elcosano.html	No date
		Definition for: Prostaglandin, http://www.kumc.edu/instruction/medicine/pathology/ed/keywords/kw_prostagl.html	No date

EXAMINER

[Signature]

DATE CONSIDERED

3/15/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

